DOYLESTOWN PA, and OXFORD, England, 18 October 2007 - EUSA Pharma Inc (‘EUSA’), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the successful conclusion of the European Mutual Recognition Procedure for Rapydan(r). The procedure completed successfully at the “day 90" target date of 9 October 2007. Rapydan(r), a rapid-onset anaesthetic patch, is EUSA’s lead product in the large and growing pain market.
